Targeted Oncology16h
FDA Approves IND for AS1986NS, a New Approach in Prostate Cancer Research
The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.
FDA to pull common but ineffective cold medicine from market
The FDA says oral phenylephrine, used in many over-the-counter cough and cold medicines, "is not effective as a nasal ...
FDA seeks to remove ingredient from cold medicines after data shows it does not work
The U.S. Food and Drug Administration is taking the first step to remove an ingredient in non-prescription cold medicines ...
dvm3601d
FDA approves generic florfenicol drug for certain freshwater fish
Earlier this year, the FDA approved 2 new indications for Aquaflor. According to Merck, the supplemental approval increased ...
manilatimes1d
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Dupixent has been approved for CSU in Japan and the United Arab Emirates (UAE) and is also under regulatory review in the EU based on earlier study readouts. Outside of Japan and the UAE, the safety ...
UPI News on MSN8d
FDA says commonly used decongestant 'not effective,' proposes removal
director of the FDA's Center for Drug Evaluation and Research, in a news release on Thursday. Advertisement "Based on our ...
Check your cinnamon before baking a pie. FDA recalls cinnamon in CT due to high lead levels
Before you add some cinnamon to your holiday baked goods, you should check to see if your cinnamon has been recalled. The ...
Atlanta Journal-Constitution4d
FDA proposes pulling decongestants from shelves over one ingredient
For some products, it is the only ingredient, the FDA said in a news release issued Thursday. Others contain oral phenylephrine and acetaminophen, dextromethorphan or another active ingredient.
GlobalData on MSN10d
FDA approves Journey Medical’s rosacea treatment Emrosi
Journey Medical's new rosacea treatment will rival industry giant Galderma's Oracea in the treatment of rosacea.
FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs
CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of approval from the FDA ...
BioSpace1d
Adaptimmune Plots Path to FDA as Sarcoma Cell Therapy Aces Pivotal Trial
Following strong treatment response data for Adaptimmune’s lete-cel, the biotech is planning to initiate a rolling BLA ...
Sacramento Bee10d
FDA Approves Renewal of Canalevia-CA1, Jaguar Health’s Drug for Chemotherapy-Induced Diarrhea in Dogs
FDA's conditional approval allows a drug company ... Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation ...